Hungarian Gedeon Richter signs new collaboration with US AbbVie
Hungarian pharmaceutical company Gedeon Richter and US peer AbbVie on Thursday announced a new collaboration for the discovery and development of novel targets for neuropsychiatric conditions.
The collaboration expands on the success of nearly two decades of partnership on central nervous system products, such as cariprazine and the discovery of investigational drug candidate ABBV-932 for the treatment of bipolar depression and generalised anxiety disorder.
Under the terms of the agreement, the collaboration includes both preclinical and clinical R+D activities with shared financing by the parties. Richter will receive an upfront cash payment of USD 25m, along with potential future development, regulatory and commercialisation milestones. Richter may also receive sales-based royalties. AbbVie will have worldwide commercialisation rights except for the traditional markets of Richter, including Europe, Russia, other CIS countries and Vietnam.
Read also:
- Read the story of Gedeon Richter, the founder of the world-famous Hungarian pharmaceutical corporation HERE
- Explosion at a pharmaceutical factory in Budapest
please make a donation here
Hot news
Ghostly chronicles: Unveiling spooky Hungarian legends – VIDEO
Masses of Hungarians move to live and work in Austria
Hungarian Speaker: “No issue is more important in Europe today than demography”
Wizz Air plane hit by lightning… twice – the pilot did something unexpected
IMF: Hungarian economy will be a frontrunner in the EU next year
VIDEO: Deranged Hungarian set ferrets on small, tied-up dog and cheered on every bite